Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06551324 · ClinicalTrials.gov registry record · Phase 3
A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).
A Phase 3 study of Metastatic Castrate Resistant Prostate Cancer (mCRPC), sponsored by Pfizer.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 600
- Enrollment target
- 20
- Study locations
NCT06551324: Recruiting Phase 3 study of Metastatic Castrate Resistant Prostate Cancer (mCRPC), sponsored by Pfizer.
NCT06551324 is a Phase 3 study of Metastatic Castrate Resistant Prostate Cancer (mCRPC) that is actively recruiting participants, run by Pfizer. The registered enrollment target is 600 participants, above the 50-participant average among 3 other Metastatic Castrate Resistant Prostate Cancer (mCRPC) trials with a reported enrollment target (1100% higher). The trial reports 20 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06551324, a Phase 3 study of Metastatic Castrate Resistant Prostate Cancer (mCRPC), is actively recruiting participants, sponsored by Pfizer.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 600 participants
- Enrollment target
- 20
- Study locations
Study Summary
Pfizer MEVPRO-1 (C2321014) is a randomized, open-label, multi-center clinical trial evaluating whether combining the study medicine (PF-06821497) with enzalutamide is safe and effective compared to physician's choice of either second-line androgen receptor (AR) directed therapy with enzalutamide or docetaxel (chemotherapy) for treating metastatic castration-resistant prostate cancer (mCRPC) after progression on prior abiraterone acetate treatment. The primary objective of this clinical trial is to assess the radiographic progression free survival (rPFS) of the combination of PF-06821497 plus enzalutamide versus physician's choice of enzalutamide or docetaxel.
Primary Outcome
rPFS is defined as the time from the date of randomization to first objective evidence of radiographic progression as assessed in soft tissue per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or in bone per Prostate Cancer Clinical Trials Working Group 3 (PCWG3) guidelines by BICR, or death, whichever occurs first.
Conditions Studied
Interventions
- DRUG Docetaxel
- DRUG Enzalutamide
- DRUG PF-06821497
Study Locations (20)
California
- Los Angeles Cancer Network - Anaheim
- UCSF Cancer Center Berkeley - Berkeley
- UCSF Cancer Center Burlingame - Burlingame
- Los Angeles Cancer Network - Fountain Valley
- Los Angeles Cancer Network - Glendale
- Los Angeles Cancer Network - Glendale
- Los Angeles Cancer Network - Los Angeles
- Los Angeles Cancer Network - Los Angeles
- Stanford Cancer Center - Palo Alto
- UCSF Investigational Drug Pharmacy - San Francisco
- UCSF Medical Center at Mission Bay - San Francisco
- UCSF Cancer Center San Mateo - San Mateo
Arizona
- Ironwood Cancer & Research Centers - Chandler
- Ironwood Cancer & Research Centers - Gilbert
- Ironwood Cancer & Research Centers - Glendale
- Ironwood Cancer & Research Centers - Mesa
- Ironwood Cancer & Research Centers - Mesa
- Ironwood Cancer & Research Centers - Phoenix
- Ironwood Cancer & Research Centers - Scottsdale
Alabama
- Urology Centers of Alabama - Homewood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2024-10-21 |
| Est. Completion | 2028-10-29 |
| Phase | Phase 3 |
What NCT06551324 shows while recruiting
NCT06551324 is an interventional study that assigns participants to a tested intervention. The registered 600 participants enrollment target is mid-sized for trials with a published cap, above the 50-participant average among 3 other Metastatic Castrate Resistant Prostate Cancer (mCRPC) trials with a reported enrollment target (1100% higher).
The record links to 1 condition, with Metastatic Castrate Resistant Prostate Cancer (mCRPC) appearing as the primary indexed condition, and to 3 interventions - of which Docetaxel is the first listed.
NCT06551324 names 20 study sites across 3 states, led by California, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT06551324 about?
NCT06551324 is a clinical study titled "A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).". Pfizer MEVPRO-1 (C2321014) is a randomized, open-label, multi-center clinical trial evaluating whether combining the study medicine (PF-06821497) with enzalutamide is safe and effective compared to physician's choice of either second-line androgen receptor (AR) directed therapy with enzalutamide or ...
What is the current status of trial NCT06551324?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 600 participants. The study started on 2024-10-21. Estimated completion is 2028-10-29.
What conditions does trial NCT06551324 study?
This clinical trial studies the following conditions: Metastatic Castrate Resistant Prostate Cancer (mCRPC).
What interventions are being tested in trial NCT06551324?
The interventions under investigation include: Docetaxel (DRUG), Enzalutamide (DRUG), PF-06821497 (DRUG).
Who is sponsoring clinical trial NCT06551324?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06551324 being conducted?
This trial has 20 study locations across Alabama, Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
RECRUITING · Phase 1
-
TmPSMA-02 in mCRPC
RECRUITING · Phase 1
-
Safety, Tolerability, and PK of GT0918 (Proxalutamide) in Subjects With Metastatic Castrate Prostate Cancer
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004317 · 600 participants · Phase 4
Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
- NCT00209235 · 600 participants · NA
Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments
- NCT01473784 · 600 participants · NA
Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
- NCT01866371 · 600 participants
High Resolution Retinal Imaging
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI